New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine.   The findings from a double blinded randomized a Phase IIb/IIIa study combining nimotuzumab with gemcitabine in 192 patients with locally advanced or metastatic pancreatic cancer patients was recently published in the Annals of Oncology (Issue 10, 1 Oct 2017).   A total of 192 patients were randomly assigned to receive either nimotuzumab plus gemcitabine, or gemcitabine alone, with 1-year overall survival rates of 34% versus 19%, and median overall survival durations of 8.6 months versus 6.0 months, respectively (HR = 0.69; P = 0.0341). In addition progression free survival durations was observed at 4.43 months in the treatment arm versus 3.47 months in the control (HR = 0.68; P = 0.0163).   In a sub-group analysis, patients with pancreatic cancer KRAS-wild-type disease who received nimotuzumab had significantly longer overall survival than those with pancreatic cancer KRAS-mutant disease (11.6 months versus 5.6 months).   The randomized study showed that nimotuzumab in combination with gemcitabine is safe and well tolerated and that the 1-year OS and PFS rates for the entire population were significantly improved. The study met its primary objectives.   To access the full publication please visit: https://academic.oup.com/annonc/article-abstract/28/10/2429/3926574?redirectedFrom=fulltext The clinical trial was sponsored and lead by Oncoscience Gmbh. The study ID was: OSAG-101-PCS-07